Real-World data reveals how breast cancer patients fare on palbociclib
NCT ID NCT04498481
First seen Feb 28, 2026 · Last updated May 22, 2026 · Updated 12 times
Summary
This study looked back at medical records of women with advanced or metastatic HR+/HER2- breast cancer who received palbociclib combined with hormone therapy in community clinics. The goal was to see how doctors actually prescribe these treatments and what outcomes patients experience, like how long they live or how long the cancer stays controlled. No new treatments were given; it was purely an observation of existing care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer United States
New York, New York, 10017, United States
Conditions
Explore the condition pages connected to this study.